You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Pafolacianine sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for pafolacianine sodium and what is the scope of freedom to operate?

Pafolacianine sodium is the generic ingredient in one branded drug marketed by On Target Labs and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Pafolacianine sodium has thirty-five patent family members in twelve countries.

One supplier is listed for this compound.

Summary for pafolacianine sodium
International Patents:35
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:pafolacianine sodium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pafolacianine sodium
Generic Entry Date for pafolacianine sodium*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for pafolacianine sodium
Anatomical Therapeutic Chemical (ATC) Classes for pafolacianine sodium

US Patents and Regulatory Information for pafolacianine sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
On Target Labs CYTALUX pafolacianine sodium SOLUTION;INTRAVENOUS 214907-001 Nov 29, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for pafolacianine sodium

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2014143309 ⤷  Sign Up
Japan 2017149776 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物 (SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUP CONJUGATED TO COMPOUND USED FOR THE TARGETED IMAGING OF TUMOR) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2014149069 ⤷  Sign Up
European Patent Office 2972320 IMAGERIE PAR FLUORESCENCE DE MALADIES INFLAMMATOIRES (METHODS OF IMAGING INFLAMMATORY DISEASES BY LIGANDS CONJUGATED TO FLUORESCENT COMPOUNDS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.